Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies

NCT04503265 is registered in ClinicalTrials.gov with AtlasMedx, Incorporated as lead sponsor.

NCT NCT04503265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04503265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open Label, Multi-center, Non-randomized Dose Escalation and Dose Expansion Study of AMXI-5001 in Patients With Advanced Malignancies
Lead sponsor
AtlasMedx, Incorporated
Phase
Phase 1/2
Overall status
Recruiting
Start date
August 12, 2020
Completion date
October 31, 2026
Enrollment
122 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced malignant neoplasm, breast cancer, homologous recombination deficiency, ovarian cancer, pancreatic cancer, prostate cancer